Skip to content

Accelerant Holdings

US · ARX #2245 by market cap Listed 2025
19.75 +0.02 +0.10%
Live - 5344 symbols - heartbeat 194s ago · 2026-10-08 06:31
Pre-market 19.70 -0.25%
After-hours 19.75 0.00%
Market cap
4.29B
P/B
5.98
EPS
-6.42
Reader sentiment Are you bullish or bearish on ARX?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 5.97 Expensive vs history 89th percentile
5-year average -16.75 · #16 of 22 in Insurance Brokers
P/E ratio -3.13 Cheap vs history 5th percentile
5-year average 21.63 · forward 62.74
P/S ratio 3.74 In line with history 59th percentile
5-year average 4.01 · forward 3.67 · #20 of 25 in Insurance Brokers

Vs. peers Insurance Brokers

Company Market cap P/E (TTM) P/B Div yield
Accelerant Holdings (ARX) 4.29B -3.13 5.98 0.00%
Marsh (MRSH) 82.87B 21.20 5.46 2.07%
Arthur J. Gallagher (AJG) 58.21B 37.66 2.45 1.19%
Aon PLC (AON) 57.37B 14.91 5.98 1.13%
Willis Towers Watson (WTW) 27.00B 18.00 3.51 1.29%
Brown & Brown (BRO) 20.65B 19.72 1.64 1.05%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value27.74 Economic moatNone UncertaintyHigh

Trading 40.5% below Morningstar's fair value estimate.

Fair value

While Accelerant Holdings may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 29% discount to our quantitative fair value estimate of $27.74 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet increases our estimated fair value. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of -12.8 lies in the bottom 10% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 16.8%, a core component of valuation, falls in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 06:31:01 · For reference only, not investment advice and not tailored to your situation.